Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc.

Biotechnology • Healthcare • Rockville, MD, United States • AVTX (NCM)

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

410 522 8707 540 Gaither Road, Rockville, MD 20850, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) - Yahoo Finance
Yahoo Finance • Oct 29
Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug - Stocktwits
Stocktwits • Oct 22
Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat
MarketBeat • Dec 19
Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains - simplywall.st
simplywall.st • Sep 16
Mizuho initiates Avalo Therapeutics stock with Outperform rating on HS drug potential - Investing.com
Investing.com • Dec 17

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Avalo Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Avalo Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Avalo Therapeutics, Inc. have?
Avalo Therapeutics, Inc. has approximately 23 employees.
What industry is Avalo Therapeutics, Inc. in?
Avalo Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Avalo Therapeutics, Inc. a publicly traded company?
Yes, Avalo Therapeutics, Inc. is publicly traded under the ticker symbol AVTX on the NCM. The company has a market capitalization of approximately $0.33 billion.
Where is Avalo Therapeutics, Inc. headquartered?
Avalo Therapeutics, Inc. is headquartered in Rockville, MD, United States at 540 Gaither Road, Rockville, MD 20850, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.